Abstracts

Filters

Clear Filters
All Days Sun, Sep 28 Mon, Sep 29 Tue, Sep 30 Wed, Oct 01

Tuesday, September 30

2:50 PM - 3:00 PM PT

331 - Prospective Study of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cells for Relapsed/Refractory B-Cell Lymphomas
Speaker: Imber, Brandon, MD, MS - Memorial Sloan Kettering Cancer Center, New York, NY
2:50 PM - 3:00 PM PT

336 - An Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery
Speaker: Zhao, Jingtong, MS, BS - Duke University, Durham, NC
3:00 PM - 3:10 PM PT

332 - Differential Impact of Total Body Irradiation- vs. Chemotherapy-Based Myeloablative Conditioning on Oral Microbiota and Mucositis after Allogeneic Transplantation
Speaker: Ebadi, Maryam, MD - University of Washington, Seattle, WA
3:00 PM - 3:10 PM PT

337 - Independent External Validation of Radiation-Induced Esophagitis Prediction during Chemoradiation Therapy for NSCLC Using RTOG 0617 Trial Data
Speaker: Cella, Laura, PhD - National Research Council (IBB), Napoli, Campania
3:10 PM - 3:20 PM PT

333 - Updated Results of RESTART Protocol (<em>R</em>adioth<em>E</em>rapy bridging and con<em>S</em>olida<em>T</em>ion for C<em>AR-T</em>) in Large B-cell Lymphoma
Speaker: Mikhaeel, George, MD, MBBS - Guys and St. Thomas NHS Foundation Trust, London, London
3:10 PM - 3:20 PM PT

338 - Interpretable Deep Learning Predicts Metastasis-Free Survival (MFS) from Conventional Imaging for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC) Using Multi-Modality PSMA PET and CT Ima
Speaker: Cao, Yufeng, PhD - University of Maryland Central Maryland Radiation Oncology, Columbia, MD
3:20 PM - 3:30 PM PT

339 - 3D topological analysis for assessing therapeutic responses to radiation and chemotherapy with and without anti-CD40 immunotherapy in local advanced rectal cancer
Speaker: Zhang, Haozhao, MS - UT Southwestern Medical Center, Dallas, TX
3:30 PM - 3:40 PM PT

340 - Radiotherapy-Induced Acute Lymphopenia for Low and Intermediate Risk Prostate Cancer
Speaker: Moteabbed, Maryam, PhD - Massachusetts General Hospital, Boston, MA
4:00 PM - 4:10 PM PT

341 - Survival Outcomes of Induction Immunotherapy Combined with Platinum-Based Doublet Chemotherapy Followed by Immunotherapy and Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer: A Phase II
Speaker: Yuan, Yi-Di, DO - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing
4:00 PM - 4:10 PM PT

346 - Differential Survival Benefits of PORT in AJCC-9th /IASLC-Defined N2 NSCLC Substages: A Multicenter Real-World Study
Speaker: Bao, Yongxing, MD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC, Beijing, Beijing
4:00 PM - 5:00 PM PT

CNS 4: Quick Pitch: Trials, Toxicity, and Translational Updates in CNS
Speaker: Tringale, Kathryn, MD, MS - UC San Diego, La Jolla, CA
4:00 PM - 5:00 PM PT

CNS 4: Quick Pitch: Trials, Toxicity, and Translational Updates in CNS
Speaker: Kleinberg, Lawrence, MD - Johns Hopkins University, Baltimore, MD